The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic and autoimmune diseases.
Antigen Express said that the proprietary vaccine being developed is an off-the-shelf product designed to reduce the risk of relapse in cancer patients.
It is the subject of a controlled, randomised Phase II trial in patients with breast cancer which has yielded positive interim results.
Based on positive results from a Phase I trial in prostate cancer patients, preparations for a Phase II clinical trial in prostate cancer patients are underway.
In all studies, the self-potentiating vaccine has shown very low toxicity and generates a good immune response.
Generex is engaged in the research, development and commercialisation of drug delivery systems and technologies. The company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).
The Generex’s buccal insulin spray product, Generex Oral-lyn, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.